CL-387785(Synonyms: EKI-785; WAY-EKI 785)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CL-387785 (Synonyms: EKI-785; WAY-EKI 785) 纯度: 98.10%

CL-387785 (EKI785; WAY-EKI 785) 是一种不可逆的 EGFR 抑制剂，IC50 为 370 pM。

CL-387785(Synonyms: EKI-785; WAY-EKI 785)

CL-387785 Chemical Structure

CAS No. : 194423-06-8

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥663 In-stock
2 mg ￥550 In-stock
5 mg ￥790 In-stock
10 mg ￥1250 In-stock
25 mg ￥2800 In-stock
50 mg ￥5100 In-stock
100 mg ￥8000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

CL-387785 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Covalent Screening Library
  • Differentiation Inducing Compound Library
  • Anti-Hepatitis C Virus Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370 pM.

IC50 & Target

EGFR

370 pM (IC50)

分子量

381.23

Formula

C18H13BrN4O
CAS 号

194423-06-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 13.67 mg/mL (35.86 mM; Need ultrasonic and warming)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.6231 mL 13.1154 mL 26.2309 mL
5 mM 0.5246 mL 2.6231 mL 5.2462 mL
10 mM 0.2623 mL 1.3115 mL 2.6231 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Discafani CM, et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem Pharmacol. 1999 Apr 15;57(8):917-25.

    [2]. Sweeney WE, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000 Jan;57(1):33-40.

    [3]. Greulich H, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov;2(11):e313.

    [4]. Kobayashi S, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005 Aug 15;65(16):7096-101.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务